Skip Content
You are currently on the new version of our website. Access the old version .

228 Results Found

  • Review
  • Open Access
59 Citations
10,691 Views
15 Pages

Multiple Roles of PLK1 in Mitosis and Meiosis

  • Jaroslav Kalous and
  • Daria Aleshkina

2 January 2023

Cells are equipped with a diverse network of signaling and regulatory proteins that function as cell cycle regulators and checkpoint proteins to ensure the proper progression of cell division. A key regulator of cell division is polo-like kinase 1 (P...

  • Article
  • Open Access
2 Citations
2,928 Views
21 Pages

PLK1 Regulates MicroRNA Biogenesis through Drosha Phosphorylation

  • Claire Emily Fletcher,
  • Molly Ann Taylor and
  • Charlotte Lynne Bevan

19 September 2023

Polo-Like Kinase 1 (PLK1), a key mediator of cell-cycle progression, is associated with poor prognosis and is a therapeutic target in a number of malignancies. Putative phosphorylation sites for PLK1 have been identified on Drosha, the main catalytic...

  • Review
  • Open Access
14 Citations
5,774 Views
14 Pages

The accurate distribution of the replicated genome during cell division is essential for cell survival and healthy organismal development. Errors in this process have catastrophic consequences, such as birth defects and aneuploidy, a hallmark of canc...

  • Article
  • Open Access
24 Citations
9,908 Views
27 Pages

Molecular Targeting of the Oncoprotein PLK1 in Pediatric Acute Myeloid Leukemia: RO3280, a Novel PLK1 Inhibitor, Induces Apoptosis in Leukemia Cells

  • Na-Na Wang,
  • Zhi-Heng Li,
  • He Zhao,
  • Yan-Fang Tao,
  • Li-Xiao Xu,
  • Jun Lu,
  • Lan Cao,
  • Xiao-Juan Du,
  • Li-Chao Sun and
  • Jian Pan
  • + 17 authors

7 January 2015

Polo-like kinase 1 (PLK1) is highly expressed in many cancers and therefore a biomarker of transformation and potential target for the development of cancer-specific small molecule drugs. RO3280 was recently identified as a novel PLK1 inhibitor; how...

  • Article
  • Open Access
22 Citations
5,530 Views
10 Pages

Wee1 Rather Than Plk1 Is Inhibited by AZD1775 at Therapeutically Relevant Concentrations

  • Angela Flavia Serpico,
  • Giuseppe D’Alterio,
  • Cinzia Vetrei,
  • Rosa Della Monica,
  • Luca Nardella,
  • Roberta Visconti and
  • Domenico Grieco

13 June 2019

Wee1 kinase is an inhibitor of cyclin-dependent kinase (cdk)s, crucial cell cycle progression drivers. By phosphorylating cdk1 at tyrosine 15, Wee1 inhibits activation of cyclin B-cdk1 (Cdk1), preventing cells from entering mitosis with incompletely...

  • Article
  • Open Access
32 Citations
4,301 Views
14 Pages

Identification of PLK1 as a New Therapeutic Target in Mucinous Ovarian Carcinoma

  • Roberta Affatato,
  • Laura Carrassa,
  • Rosaria Chilà,
  • Monica Lupi,
  • Valentina Restelli and
  • Giovanna Damia

13 March 2020

Mucinous epithelial ovarian cancer (mEOC) is a rare subset of epithelial ovarian cancer. When diagnosed at a late stage, its prognosis is very poor, as it is quite chemo-resistant. To find new therapeutic options for mEOC, we performed high-throughpu...

  • Review
  • Open Access
1,338 Views
17 Pages

Polo-like Kinase 1 (PLK1) Inhibitors Targeting Anticancer Activity

  • Dina Bárbara Aguado-Herrera,
  • Yudith Cañizares-Carmenate and
  • Edeildo Ferreira da Silva-Júnior

Polo-like kinase 1 (PLK1) is a serine/threonine kinase that orchestrates multiple critical events during mitosis, including centrosome maturation, spindle assembly, kinetochore–microtubule attachment, and cytokinesis. Dysregulation and overexpr...

  • Article
  • Open Access
18 Citations
4,811 Views
14 Pages

A Regulatory Loop of FBXW7-MYC-PLK1 Controls Tumorigenesis of MYC-Driven Medulloblastoma

  • Dong Wang,
  • Angela Pierce,
  • Bethany Veo,
  • Susan Fosmire,
  • Etienne Danis,
  • Andrew Donson,
  • Sujatha Venkataraman and
  • Rajeev Vibhakar

21 January 2021

Polo-like kinase 1 (PLK1) is highly expressed in group 3 medulloblastoma (MB), and it has been preclinically validated as a cancer therapeutic target in medulloblastoma. Here, we demonstrate that PLK1 inhibition with PCM-075 or BI6727 significantly r...

  • Communication
  • Open Access
5 Citations
3,405 Views
15 Pages

Design and Synthesis of a Novel PLK1 Inhibitor Scaffold Using a Hybridized 3D-QSAR Model

  • Youri Oh,
  • Hoyong Jung,
  • Hyejin Kim,
  • Jihyun Baek,
  • Joonhong Jun,
  • Hyunwook Cho,
  • Daseul Im and
  • Jung-Mi Hah

Polo-like kinase 1 (PLK1) plays an important role in cell cycle progression and proliferation in cancer cells. PLK1 also contributes to anticancer drug resistance and is a valuable target in anticancer therapeutics. To identify additional effective P...

  • Article
  • Open Access
22 Citations
8,658 Views
27 Pages

Combined Pharmacophore Modeling, Docking, and 3D-QSAR Studies of PLK1 Inhibitors

  • Shuai Lu,
  • Hai-Chun Liu,
  • Ya-Dong Chen,
  • Hao-Liang Yuan,
  • Shan-Liang Sun,
  • Yi-Ping Gao,
  • Pei Yang,
  • Liang Zhang and
  • Tao Lu

1 December 2011

Polo-like kinase 1, an important enzyme with diverse biological actions in cell mitosis, is a promising target for developing novel anticancer drugs. A combined molecular docking, structure-based pharmacophore modeling and three-dimensional quantitat...

  • Article
  • Open Access
10 Citations
4,046 Views
19 Pages

Combinatorial Effect of PLK1 Inhibition with Temozolomide and Radiation in Glioblastoma

  • Arvind Pandey,
  • Satyendra C. Tripathi,
  • Junhua Mai,
  • Samir M. Hanash,
  • Haifa Shen,
  • Sankar Mitra and
  • Robert C. Rostomily

12 October 2021

New strategies that improve median survivals of only ~15–20 months for glioblastoma (GBM) with the current standard of care (SOC) which is concurrent temozolomide (TMZ) and radiation (XRT) treatment are urgently needed. Inhibition of polo-like kinase...

  • Article
  • Open Access
2 Citations
1,597 Views
19 Pages

N-Degron-Based PROTAC Targeting PLK1: A Potential Therapeutic Strategy for Cervical Cancer

  • Pethaiah Gunasekaran,
  • Sang Chul Shin,
  • Yeon Sil Hwang,
  • Jihyeon Lee,
  • Yeo Kyung La,
  • Min Su Yim,
  • Hak Nam Kim,
  • Tae Wan Kim,
  • Eunjung Yang and
  • Jeong Kyu Bang
  • + 5 authors

Background: Cervical cancer remains a major global health concern, with existing chemotherapy facing limited effectiveness owing to resistance. Polo-like kinase 1 (PLK1) overexpression in cervical cancer cells is a promising target for developing nov...

  • Review
  • Open Access
19 Citations
4,834 Views
10 Pages

24 February 2022

Centrosomes nucleate and anchor microtubules and therefore play major roles in spindle formation and chromosome segregation during mitosis. Duplication of the centrosome occurs, similar to DNA, only once during the cell cycle. Aberration of the centr...

  • Article
  • Open Access
6 Citations
3,738 Views
15 Pages

21 September 2022

Cancer continues to be one of the world’s most severe public health issues. Polo-like kinase 1 (PLK1) is one of the most studied members of the polo-like kinase subfamily of serine/threonine protein kinases. PLK1 is a key mitotic regulator resp...

  • Article
  • Open Access
21 Citations
4,387 Views
15 Pages

16 November 2020

USP7 is a promising target for the development of cancer treatments because of its high expression and the critical functions of its substrates in carcinogenesis of several different carcinomas. Here, we demonstrated the effectiveness of targeting US...

  • Article
  • Open Access
8 Citations
4,613 Views
21 Pages

Dual Targeting of EGFR with PLK1 Exerts Therapeutic Synergism in Taxane-Resistant Lung Adenocarcinoma by Suppressing ABC Transporters

  • Sol-Bi Shin,
  • Dae-Hoon Kim,
  • Da-Eun Kim,
  • Mark Borris D. Aldonza,
  • Yoosik Kim and
  • Hyungshin Yim

1 September 2021

To overcome the limitations of chemoresistance, combination therapies using druggable targets have been investigated. Our previous studies led us to hypothesize that the downregulation of PLK1 expression or activity can be one strategy to overcome th...

  • Communication
  • Open Access
5 Citations
3,557 Views
14 Pages

2 May 2023

Tyrosine kinase inhibitors (TKI) targeting the epidermal growth factor receptor (EGFR) have significantly prolonged survival in EGFR-mutant non-small cell lung cancer patients. However, the development of resistance mechanisms prohibits the curative...

  • Article
  • Open Access
3 Citations
4,887 Views
14 Pages

19 September 2020

Cells recovering from the G2/M DNA damage checkpoint rely more on Aurora A-PLK1 signaling than cells progressing through an unperturbed G2 phase, but the reason for this discrepancy is not known. Here, we devised a method based on a FRET reporter for...

  • Article
  • Open Access
11 Citations
4,496 Views
22 Pages

Mitotic Acetylation of Microtubules Promotes Centrosomal PLK1 Recruitment and Is Required to Maintain Bipolar Spindle Homeostasis

  • Sylvia Fenosoa Rasamizafy,
  • Claude Delsert,
  • Gabriel Rabeharivelo,
  • Julien Cau,
  • Nathalie Morin and
  • Juliette van Dijk

22 July 2021

Tubulin post-translational modifications regulate microtubule properties and functions. Mitotic spindle microtubules are highly modified. While tubulin detyrosination promotes proper mitotic progression by recruiting specific microtubule-associated p...

  • Article
  • Open Access
9 Citations
4,338 Views
27 Pages

Combined Inhibition of UBE2C and PLK1 Reduce Cell Proliferation and Arrest Cell Cycle by Affecting ACLY in Pan-Cancer

  • Keying Liang,
  • Qian Wang,
  • Li Qiu,
  • Xiaocheng Gong,
  • Zixi Chen,
  • Haibo Zhang,
  • Ke Ding,
  • Yunfei Liu,
  • Jinfen Wei and
  • Hongli Du
  • + 2 authors

27 October 2023

Various studies have shown that the cell-cycle-related regulatory proteins UBE2C, PLK1, and BIRC5 promote cell proliferation and migration in different types of cancer. However, there is a lack of in-depth and systematic research on the mechanism of...

  • Article
  • Open Access
5 Citations
3,396 Views
26 Pages

CEBP-β and PLK1 as Potential Mediators of the Breast Cancer/Obesity Crosstalk: In Vitro and In Silico Analyses

  • Felice Maria Accattatis,
  • Amanda Caruso,
  • Alfonso Carleo,
  • Piercarlo Del Console,
  • Luca Gelsomino,
  • Daniela Bonofiglio,
  • Cinzia Giordano,
  • Ines Barone,
  • Sebastiano Andò and
  • Stefania Catalano
  • + 1 author

22 June 2023

Over the last two decades, obesity has reached pandemic proportions in several countries, and expanding evidence is showing its contribution to several types of malignancies, including breast cancer (BC). The conditioned medium (CM) from mature adipo...

  • Article
  • Open Access
2 Citations
3,015 Views
18 Pages

27 February 2024

E. sinensis is an animal model for studying the reproduction and development of crustaceans. In this study, we knocked down the Es-Kif2a gene by injecting dsRNA into E. sinensis and inhibited Es-Plk1 gene expression by injecting PLK1 inhibitor BI6727...

  • Article
  • Open Access
14 Citations
5,727 Views
16 Pages

CDC2 Is an Important Driver of Vascular Smooth Muscle Cell Proliferation via FOXM1 and PLK1 in Pulmonary Arterial Hypertension

  • Ruma Pal-Ghosh,
  • Danfeng Xue,
  • Rod Warburton,
  • Nicholas Hill,
  • Peter Polgar and
  • Jamie L. Wilson

A key feature of pulmonary arterial hypertension (PAH) is the hyperplastic proliferation exhibited by the vascular smooth muscle cells from patients (HPASMC). The growth inducers FOXM1 and PLK1 are highly upregulated in these cells. The mechanism by...

  • Article
  • Open Access
13 Citations
2,476 Views
16 Pages

Increased hsa-miR-100-5p Expression Improves Hepatocellular Carcinoma Prognosis in the Asian Population with PLK1 Variant rs27770A>G

  • Zhouxiang Liao,
  • Qi Zhang,
  • Lichao Yang,
  • Hui Li,
  • Wanling Mo,
  • Zhenyu Song,
  • Xuejing Huang,
  • Sha Wen,
  • Xiaojing Cheng and
  • Min He

27 December 2023

Hepatocellular carcinoma (HCC) has the highest incidence and mortality in the Asian population, and race is an independent risk factor affecting survival time in liver cancer. Micro RNAs (miRNAs) are remarkably dysregulated in HCC and closely associa...

  • Article
  • Open Access
45 Citations
8,658 Views
17 Pages

7 April 2022

Breast cancer is one of the most common malignant tumors in women worldwide. Early diagnosis, treatment, and prognosis of breast cancer are global challenges. Identification of valid predictive diagnosis and prognosis biomarkers and drug targets are...

  • Article
  • Open Access
24 Citations
4,958 Views
15 Pages

3D-QSAR Studies, Molecular Docking, Molecular Dynamic Simulation, and ADMET Proprieties of Novel Pteridinone Derivatives as PLK1 Inhibitors for the Treatment of Prostate Cancer

  • Mohammed Er-rajy,
  • Mohamed El fadili,
  • Hamada Imtara,
  • Aamir Saeed,
  • Abid Ur Rehman,
  • Sara Zarougui,
  • Shaef A. Abdullah,
  • Ahmad Alahdab,
  • Mohammad Khalid Parvez and
  • Menana Elhallaoui

2 January 2023

Overexpression of polo-like kinase 1 (PLK1) has been found in many different types of cancers. With its essential role in cell proliferation, PLK1 has been determined to be a broad-spectrum anti-cancer target. In this study, 3D-QSAR, molecular dockin...

  • Article
  • Open Access
9 Citations
3,719 Views
28 Pages

15 September 2023

Structural-based drug design and solvent-free synthesis were combined to obtain three novel series of 5-arylethylidene-aminopyrimidine-2,4-diones (4, 5ac, 6a,b), 5-arylethylidene-amino-2-thiopyrimidine-4-ones (7,8), and 6-arylpteridines (9,10)...

  • Article
  • Open Access
13 Citations
5,502 Views
22 Pages

17 September 2022

Ovarian cancer (OC) accounts for approximately 4% of cancer deaths in women worldwide and is the deadliest gynecologic malignancy. High-grade serous ovarian cancer (HGSOC) is the most predominant ovarian cancer, in which BRCA1/2 gene mutation ranges...

  • Article
  • Open Access
73 Citations
1,826 Views
8 Pages

Phase I Study of the Plk1 Inhibitor BI 2536 Administered Intravenously on Three Consecutive Days in Advanced Solid Tumours

  • A. Frost,
  • K. Mross,
  • S. Steinbild,
  • S. Hedbom,
  • C. Unger,
  • R. Kaiser,
  • D. Trommeshauser and
  • G. Munzert

1 February 2012

Background: This open-label phase i study with an accelerated titration design was performed to determine the maximum tolerated dose of BI 2536, a potent, highly selective small-molecule polo-like kinase 1 (Plk1) inhibitor. Methods: Patients with adv...

  • Article
  • Open Access
11 Citations
3,709 Views
19 Pages

10 February 2024

PLK1 is found to be highly expressed in various types of cancers, but the development of inhibitors for it has been slow. Most inhibitors are still in clinical stages, and many lack the necessary selectivity and anti-tumor effects. This study aimed t...

  • Article
  • Open Access
14 Citations
5,557 Views
25 Pages

Aurora Borealis (Bora), Which Promotes Plk1 Activation by Aurora A, Has an Oncogenic Role in Ovarian Cancer

  • Alfonso Parrilla,
  • Marta Barber,
  • Blanca Majem,
  • Josep Castellví,
  • Juan Morote,
  • José Luis Sánchez,
  • Asunción Pérez-Benavente,
  • Miguel F. Segura,
  • Antonio Gil-Moreno and
  • Anna Santamaria

6 April 2020

Identifying novel actionable factors that critically contribute to tumorigenesis is essential in ovarian cancer, an aggressive and disseminative tumor, with limited therapeutic options available. Here we show that Aurora Borealis (BORA), a mitotic pr...

  • Article
  • Open Access
4 Citations
5,162 Views
15 Pages

PLK1 Inhibitor Onvansertib Enhances the Efficacy of Alpelisib in PIK3CA-Mutated HR-Positive Breast Cancer Resistant to Palbociclib and Endocrine Therapy: Preclinical Insights

  • Sreeja Sreekumar,
  • Elodie Montaudon,
  • Davis Klein,
  • Migdalia E. Gonzalez,
  • Pierre Painsec,
  • Héloise Derrien,
  • Laura Sourd,
  • Tod Smeal,
  • Elisabetta Marangoni and
  • Maya Ridinger

25 September 2024

Background: Endocrine therapy (ET) combined with cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) is the preferred first-line treatment for hormone receptor-positive (HR+)/HER2- metastatic breast cancer. Although this is beneficial, acquired resistan...

  • Article
  • Open Access
10 Citations
3,379 Views
17 Pages

Navitoclax Enhances the Therapeutic Effects of PLK1 Targeting on Lung Cancer Cells in 2D and 3D Culture Systems

  • Bárbara Pinto,
  • Pedro Novais,
  • Ana C. Henriques,
  • Juliana Carvalho-Tavares,
  • Patrícia M. A. Silva and
  • Hassan Bousbaa

The efficacy of antimitotics is limited by slippage, whereby treated cells arrested in mitosis exit mitosis without cell division and, eventually, escape apoptosis, constituting a serious resistance mechanism to antimitotics. Strategies to overcome s...

  • Article
  • Open Access
6 Citations
3,731 Views
12 Pages

Recent evidence indicates that activation of adenosine monophosphate-activated protein kinase (AMPK), a highly conserved sensor and modulator of cellular energy and redox, regulates cell mitosis. However, the underlying molecular mechanisms for AMPK&...

  • Article
  • Open Access
22 Citations
3,276 Views
20 Pages

Pentafuhalol-B, a Phlorotannin from Brown Algae, Strongly Inhibits the PLK-1 Overexpression in Cancer Cells as Revealed by Computational Analysis

  • Waseem Ahmad Ansari,
  • Safia Obaidur Rab,
  • Mohammad Saquib,
  • Aqib Sarfraz,
  • Mohd Kamil Hussain,
  • Mohd Sayeed Akhtar,
  • Irfan Ahmad and
  • Mohammad Faheem Khan

3 August 2023

Polo-like kinase-1 (PLK-1) is an essential mitotic serine/threonine (Ser/Thr) kinase that belongs to the Polo-like kinase (PLK) family and is overexpressed in non-small cell lung cancer (NSCLC) via promotion of cell division. Therefore, PLK-1 may act...

  • Article
  • Open Access
1,903 Views
27 Pages

The plk1 Gene Regulatory Network Modeling Identifies Three Circuits for plk1-mediated Genomic Instability Leading to Neoplastic Transformation

  • Jeison F. Suescum-Holguín,
  • Diana Carolina Clavijo-Buriticá,
  • Edward Fabian Carrillo-Borda and
  • Mauricio Alberto Quimbaya

17 May 2025

Genomic instability has been increasingly recognized over the past decade as a fundamental driver of cancer initiation and progression, largely owing to its association with specific genes and cellular mechanisms that offer therapeutic potential. How...

  • Article
  • Open Access
5 Citations
3,111 Views
14 Pages

30 January 2023

The treatment for hepatocellular carcinoma (HCC), a severe cancer with a very high mortality rate, begins with the surgical resection of the primary tumor. For metastasis or for tumors that cannot be resected, sorafenib, a multi-tyrosine protein kina...

  • Article
  • Open Access
29 Citations
6,449 Views
18 Pages

POLQ Overexpression Is Associated with an Increased Somatic Mutation Load and PLK4 Overexpression in Lung Adenocarcinoma

  • Kazuya Shinmura,
  • Hisami Kato,
  • Yuichi Kawanishi,
  • Katsuhiro Yoshimura,
  • Kazuo Tsuchiya,
  • Yoshiyuki Takahara,
  • Seiji Hosokawa,
  • Akikazu Kawase,
  • Kazuhito Funai and
  • Haruhiko Sugimura

24 May 2019

DNA Polymerase Theta (POLQ) is a DNA polymerase involved in error-prone translesion DNA synthesis (TLS) and error-prone repair of DNA double-strand breaks (DSBs). In the present study, we examined whether abnormal POLQ expression may be involved in t...

  • Article
  • Open Access
1,738 Views
21 Pages

Only Infant MLL-Rearranged Leukemia Is Susceptible to an Inhibition of Polo-like Kinase 1 (PLK-1) by Volasertib

  • Jacqueline Fischer,
  • Estelle Erkner,
  • Pia Radszuweit,
  • Thomas Hentrich,
  • Hildegard Keppeler,
  • Fulya Korkmaz,
  • Julia Schulze-Hentrich,
  • Rahel Fitzel,
  • Claudia Lengerke and
  • Corina Schneidawind
  • + 1 author

27 November 2024

MLL-rearranged (MLLr) leukemia is characterized by a poor prognosis. Depending on the cell of origin, it differs in the aggressiveness and therapy response. For instance, in adults, volasertib blocking Polo-like kinase 1 (PLK-1) exhibited limited suc...

  • Article
  • Open Access
15 Citations
4,006 Views
18 Pages

23 January 2020

Even though the tumour suppressive role of PTEN is well-known, its prognostic implications are ambiguous. The objective of this study was to further explore the function of PTEN expression in human pancreatic cancer. The expression of PTEN has been d...

  • Article
  • Open Access
1 Citations
2,680 Views
13 Pages

Study on Pharmacokinetics and Metabolic Profiles of Novel Potential PLK-1 Inhibitors by UHPLC-MS/MS Combined with UHPLC-Q-Orbitrap/HRMS

  • Lin Wang,
  • Hui Lei,
  • Jing Lu,
  • Wenyan Wang,
  • Chunjiao Liu,
  • Yunjie Wang,
  • Yifei Yang,
  • Jingwei Tian and
  • Jianzhao Zhang

10 March 2023

PLK-1 (Polo-like kinase-1) plays an essential role in cytokinesis, and its aberrant expression is considered to be keenly associated with a wide range of cancers. It has been selected as an appealing target and small-molecule inhibitors have been dev...

  • Article
  • Open Access
11 Citations
4,661 Views
18 Pages

Targeting Adaptive IRE1α Signaling and PLK2 in Multiple Myeloma: Possible Anti-Tumor Mechanisms of KIRA8 and Nilotinib

  • Yusuke Yamashita,
  • Shuhei Morita,
  • Hiroki Hosoi,
  • Hiroshi Kobata,
  • Shohei Kishimoto,
  • Tatsuya Ishibashi,
  • Hiroyuki Mishima,
  • Akira Kinoshita,
  • Bradley J. Backes and
  • Shinobu Tamura
  • + 3 authors

31 August 2020

Background: Inositol-requiring enzyme 1α (IRE1α), along with protein kinase R-like endoplasmic reticulum kinase (PERK), is a principal regulator of the unfolded protein response (UPR). Recently, the ‘mono’-specific IRE1α...

  • Article
  • Open Access
10 Citations
5,854 Views
19 Pages

Further Insights into the Ciliary Gene and Protein KIZ and Its Murine Ortholog PLK1S1 Mutated in Rod-Cone Dystrophy

  • Said El Shamieh,
  • Cécile Méjécase,
  • Matteo Bertelli,
  • Angélique Terray,
  • Christelle Michiels,
  • Christel Condroyer,
  • Stéphane Fouquet,
  • Maxime Sadoun,
  • Emmanuelle Clérin and
  • Christina Zeitz
  • + 5 authors

18 October 2017

We identified herein additional patients with rod-cone dystrophy (RCD) displaying mutations in KIZ, encoding the ciliary centrosomal protein kizuna and performed functional characterization of the respective protein in human fibroblasts and of its mo...

  • Article
  • Open Access
2 Citations
1,832 Views
20 Pages

10 September 2024

The centrosome of the amoebozoan model Dictyostelium discoideum provides the best-established model for an acentriolar centrosome outside the Opisthokonta. Dictyostelium exhibits an unusual centrosome cycle, in which duplication is initiated only at...

  • Article
  • Open Access
6 Citations
3,229 Views
19 Pages

28 March 2020

Avian metapneumovirus subtype C (aMPV/C) causes an acute respiratory disease that has caused serious economic losses in the Chinese poultry industry. In the present study, we first explored the protein profile in aMPV/C-infected Vero cells using iTRA...

  • Article
  • Open Access
8 Citations
4,506 Views
13 Pages

Development of Cell Permeable NanoBRET Probes for the Measurement of PLK1 Target Engagement in Live Cells

  • Xuan Yang,
  • Jeffery L. Smith,
  • Michael T. Beck,
  • Jennifer M. Wilkinson,
  • Ani Michaud,
  • James D. Vasta,
  • Matthew B. Robers and
  • Timothy M. Willson

25 March 2023

PLK1 is a protein kinase that regulates mitosis and is both an important oncology drug target and a potential antitarget of drugs for the DNA damage response pathway or anti-infective host kinases. To expand the range of live cell NanoBRET target eng...

  • Article
  • Open Access
5 Citations
3,815 Views
16 Pages

A Novel Allosteric Inhibitor Targets PLK1 in Triple Negative Breast Cancer Cells

  • Jankiben R. Patel,
  • Prasad Thangavelu,
  • Renee M. Terrell,
  • Bridg’ette Israel,
  • Arindam Basu Sarkar,
  • A. Michael Davidson,
  • Kun Zhang,
  • Rahul Khupse and
  • Syreeta L. Tilghman

31 March 2022

While Polo-like kinase 1 (PLK1) inhibitors have shown promise in clinical settings for treating triple-negative breast cancer tumors and other solid tumors, they are limited by their ability to bind non-selectively to the ATP kinase domain. Therefore...

  • Article
  • Open Access
6 Citations
3,378 Views
10 Pages

28 November 2019

Polo-box domain of polo-like kinase 1 (PLK1-PBD) has a pivotal role in cell proliferation and could be implicated as a potential anticancer target. Although some small-molecule inhibitors have been developed, their clinical application has been restr...

  • Article
  • Open Access
511 Views
25 Pages

Differential Expression of AURKA, AURKB, and PLK1 Modulates Clinical Outcomes and Survival in Acute Myeloid Leukemia

  • Anna Karolyna da Costa Machado,
  • Beatriz Maria Dias Nogueira,
  • Deivide de Sousa Oliveira,
  • Caio Bezerra Machado,
  • Flávia Melo Cunha de Pinho Pessoa,
  • Leidivan Sousa Cunha,
  • Igor Valentim Barreto,
  • Isabelle Magalhães Farias,
  • Rodrigo Monteiro Ribeiro and
  • Caroline Aquino Moreira-Nunes
  • + 11 authors

Acute myeloid leukemia (AML) is one of the most aggressive types of leukemia, represented by the clonal proliferation of hematopoietic precursors, which mainly promotes quantitative and differentiation alterations, as well as normal hematopoiesis sup...

  • Article
  • Open Access
39 Citations
4,255 Views
21 Pages

Luteolin-Fabricated ZnO Nanostructures Showed PLK-1 Mediated Anti-Breast Cancer Activity

  • Shiva Prasad Kollur,
  • Shashanka K. Prasad,
  • Sushma Pradeep,
  • Ravindra Veerapur,
  • Sharanagouda S. Patil,
  • Raghavendra G. Amachawadi,
  • Rajendra Prasad S,
  • Ghada Lamraoui,
  • Abdulaziz A. Al-Kheraif and
  • Chandan Shivamallu
  • + 2 authors

5 March 2021

The present work describes a facile and convenient procedure for synthesizing zinc oxide nanoparticles using luteolin isolated from Eclipta alba plant (L-ZnONPs) at room temperature. The formation of as-grown L-ZnONPs was confirmed by X-ray diffracti...

of 5